Actively Recruiting
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
Led by Incyte Corporation · Updated on 2026-05-14
24
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the interstitial concentrations using the open-flow microperfusion device and plasma pharmacokinetics following multiple doses of povorcitinib or topical ruxolitinib cream in healthy adult participants.
CONDITIONS
Official Title
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to understand and willing to sign a written informed consent form
- Age between 18 and 65 years inclusive at time of consent
- Body mass index between 18.0 and 30.5 kg/m2 inclusive
- No clinically important findings on clinical, lab, or ECG screenings
- Able to swallow and keep oral medication down
- Willing to avoid pregnancy or fathering children during the study
You will not qualify if you...
- History of uncontrolled or unstable major diseases within 6 months before screening
- Any history of autoimmune disease diagnosis
- History of cardiovascular, cerebrovascular, peripheral vascular, thrombotic disease, or uncontrolled hypertension
- Abnormal ECG history or presence
- Malabsorption syndromes affecting drug absorption
- Any malignancy except treated nonmetastatic skin or cervical carcinoma
- Recent significant gastrointestinal disease or surgery affecting drug absorption
- Major surgery within 4 weeks before screening
- Blood donation or clinical study participation within 4 weeks (2 weeks for plasma-only donation)
- Blood transfusion within 4 months before check-in
- Current or recent active infectious disease needing systemic treatment
- Known active tuberculosis or history of tuberculosis
- Positive tests for HBV, HCV, or HIV unless immune due to vaccination
- Live vaccine within 3 months before first dose
- History of alcoholism or significant alcohol use in past 3 months
- Positive tests for drugs of abuse not explained by medications or diet
- Current or recent treatment with other investigational drugs or certain drug interactions
- Consumption of specific fruits or juices within 72 hours before first dose
- Significant drug allergies or hypersensitivity to study drugs or similar
- Inability to tolerate venipuncture
- Tobacco or nicotine use within 1 month before screening
- Use of prescription or nonprescription drugs within specified periods before dosing
- Pregnant or breastfeeding women
- Conditions interfering with study participation or safety
- Excessive exercise within 7 days before check-in
- Tattoos, scarring, or skin conditions at sample sites
- Prone to keloid or hypertrophic scars or wound healing disorders
- Unwillingness to avoid certain activities affecting skin healing
- Pronounced hairiness or unwillingness to avoid shaving at application sites
- Needle phobia
- Increased risk of thrombosis (e.g., personal or family history)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Axis Clinicals
Dilworth, Minnesota, United States, 56529
Actively Recruiting
Research Team
I
Incyte Corporation Call Center (US)
CONTACT
I
Incyte Corporation Call Center (ex-US)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here